NEWS

New York, N.Y., May 10, 2022 – MPN Research Foundation (MPNRF), a global organization driving research to find new and better treatments for myeloproliferative neoplasms (MPNs), a group of rare blood cancers, and Trialjectory, the AI-powered decision-support platform for patients, healthcare providers and pharmaceutical companies, today announced a joint collaboration to bring Trialjectory’s free, AI-powered clinical… Read More »MPN Research Foundation and Trialjectory Partner to Provide Advanced Clinical Trial Matching Services for Patients in Need

PhD Stanford University With so much variability of symptoms and progression among MPN patients, individualized treatment plans are critical in the management of essential thrombocythemia, polycythemia vera, and myelofibrosis. Personalized medicine in MPNs requires that we first address the challenge of patient genetic heterogeneity, according to Anandi Krishnan, PhD, including across the clinical spectrum of… Read More »Bridging a Patient’s Mutational Data and Clinical Observations to Help Predict Progression

Catriona Jamieson, MD, PhD, University of California, San Diego Why is it that only some people progress from polycythemia vera or essential thrombocythemia to myelofibrosis? And why do only some people with myelofibrosis progress to AML?   When Catriona Jamieson, MD, PhD, and her colleagues at University of California, San Diego, first asked these questions around… Read More »Studying MPNs in the Lab and in Space

https://www.youtube.com/watch?v=yaeHpBdRxJo The science of progression was the subject of a recent webinar hosted by MPN Advocacy & Education International, in partnership with the MPN Research Foundation. The recording is now available, featuring Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center, and MPNRF Chief Executive Officer Kapila Viges. Dr. Rampal serves as the foundation’s… Read More »ICYMI Webinar on Progression

Yelena Ginzburg, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Dr. Yelena Ginzburg’s research illustrates how basic research, clinical data, and clinical trial development inform each other in what is often a continuous loop between lab and clinic. Funded by a 2019-2021 MPN Challenge award, her work focuses on understanding why iron… Read More »From Lab to Clinic and Back

Our Scientific Advisory Board represents an extraordinary group of MPN thought leaders who contribute a broad range of medical, scientific, and short- and long-term strategic advice to the foundation. We greatly appreciate the commitment by all of the members of this outstanding volunteer board, and welcome five new members. • Radek Skoda, MD, PhD, University… Read More »MPN Leaders Added to Scientific Advisory Board

With a 21-year history of impactful MPN research, we’re proud of where we started, where we are, and most importantly, where we’re headed. Check out our IMPACT@21 story in this new digital report, featuring the voices of leading MPN researchers, clinicians, advocates and people living with ET, PV and MF.

“One of the biggest things that has changed in my life is I’ve had to give things up. I have visual problems (it’s like a blind spot) so I really cut down on my driving. I had to quit cooking because I made so many mistakes. I’ll walk into a room looking for something and… Read More »Voice of the Patient Report Delivered to FDA

Thanks to a robust and growing MPN research community, the 63rd Annual Meeting and Exposition of the American Society of Hematology, ASH-21, was packed with illuminating MPN developments. Summarized here are a few of the exciting ASH 2021 presentations, workshops and posters by global researchers we’re proud to have funded. In addition, some of these… Read More »ASH 2021: Features Multiple MPNRF-Funded Projects 

What’s Next? At the end of a productive meeting, day, or week, I’m always asking myself, “what’s next.” Next on my calendar, next on my list, next on the agenda. Last year, I recognized that to get to what’s next as a foundation, I first had to learn, listen, and prepare. I learned about the… Read More »New Year’s Note from CEO, Kapila Viges